4613347659

ability to shutdown innate immunity are potent systemie anti-cancer agents. Cancer Celi 4, 263-275

Sun, X., Yau, V.K., Briggs, B.J., and Whittaker, G.R. (2005). Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology 338, 53-60.

Swinteck, B.D., and Lyles, D.S. (2008). Plasma Membranę Microdomains Containing Vesicular Stomatitis Virus M Protein Are Separate from Microdomains Containing G Protein and Nucleocapsids. J. Virol. 82, 5536-5547.

Vandepol, S.B., Lefranęois, L., and Holland, J.J. (1986). Sequences of the Major Antibody Binding Epitopes of the Indiana Serotype of Vesicular Stimatitis Virus. Virol. J. 148, 312-325.

Wagner, E.K., and Hewlett, M.J. (2004). Basic Virology, 2 edn (Etat-Unis).

Whitt, M.A. (2010). Generation of VSV pseudotypes using recombinant [Delta]G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365-374.

Wollmann, G., Rogulin, V., Simon, I., Rosę, J.K., and van den Pol, A.N. (2010). Some Attenuated Variants of Vesicular Stomatitis Virus Show Enhanced Oncolytic Activity against Humań Glioblastoma Cells relative to Normal Brain Cells. J. Virol. 84, 1563-1573.

Wongthida, P., Diaz, R.M., Galivo, F., Kottke, T., Thompson, J., Melcher, A., and Vile, R. (2010). VSV Oncolytic Virotherapy in the B16 Model Depends Upon Intact MyD88 Signaling. Mol. Ther.

Ye, Z., Sun, K., Suryanarayana, K., Justice, P., Robinson, D.G., and Wagner, R.R. (1994). Membrane-binding domains and cytopathogenesis of the matrix protein of vesicular stomatitis virus. Journal of virolgy 68, 7386-7396.